The document is a slide presentation on training for product registration using the Common Technical Document (CTD) format in the global market. It provides an overview of the CTD, which was developed by the International Conference on Harmonization (ICH) to standardize the submission format for pharmaceutical product registration across the United States, Europe and Japan. The CTD format aims to streamline the registration process and reduce duplication by organizing technical documents into five modules covering administrative information, overviews and summaries, quality, nonclinical data, and clinical data. The presentation outlines the structure and content of each CTD module.
A detailed study on the guidelines that are taken for ICH which is also known as the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. The chapter deals with an overview of Quality, Safety, Efficacy and Multidisciplinary guidelines and then a detailed study on the Quality Guidelines. Also a detailed learning of Stability Testing Guidelines proposed by the International Conference for Harmonization.
A detailed study on the guidelines that are taken for ICH which is also known as the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. The chapter deals with an overview of Quality, Safety, Efficacy and Multidisciplinary guidelines and then a detailed study on the Quality Guidelines. Also a detailed learning of Stability Testing Guidelines proposed by the International Conference for Harmonization.
intertnational council for harmonization The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is a project that brings together the regulatory authorities of Europe, Japan and the United States and experts from the pharmaceutical industry in the three regions to discuss scientific and technical aspects Details of the ICH guidelines for pharmaceutical quality from Q1 to Q12 including stability analysis, evaluation of impurities and quality risk management. ICH (Full form = International Conference on Harmonisation) is a committee that provides the pharmaceutical guidelines for industries.
Quality must be built into the product, it cannot be inspected into it. The Pharmaceutical industries are experiencing a “knowledge and experience deficit” regarding the use of QbD concepts.
FDA’s emphasis on quality by design began with the recognition that increased testing does not improve product quality (this has long been recognized in other industries).In order for quality to increase, it must be built into the product. To do this requires understanding how formulation and manufacturing process variables influence product quality.Quality by Design (QbD) is a systematic approach to pharmaceutical development that begins with predefined objectives and emphasizes product and process understanding and process control, based on sound science and quality risk management. A presentation compiled from material freely available on the WEB to introduce the concepts of QbD for beginners.
The dossier is a collection of documents that contain all the technical data of pharmaceutical products to be approved\ registered\ marketed in a country.
- Whilst the realization of the CTD took many years, there is now a common format for the submission of Marketing Authorizations Applications across the three ICH regions - Europe, Japan and the USA.
- This should facilitate pharmaceutical companies to make simultaneous filings in the ICH regions as it will eliminate the extensive work previously required to convert, for example, a US dossier to an EU dossier and vice versa.
Marv Shepherd, PSM president, Member USP Package Storage and Distribution Expert Committee, and Professor at the University of Texas at Austin speaks about updates to United States Pharmacopeia's good distribution practices.
common technical document vs electronic common technical document MayankGupta851
This presentation deals with brief overview of common technical document and its electronic version that is implemented by three ICH regions and common format for the dossier preparation for NDA application and documents required to prepare types of modules in database in specified format as specified by regulatory authorities.
intertnational council for harmonization The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is a project that brings together the regulatory authorities of Europe, Japan and the United States and experts from the pharmaceutical industry in the three regions to discuss scientific and technical aspects Details of the ICH guidelines for pharmaceutical quality from Q1 to Q12 including stability analysis, evaluation of impurities and quality risk management. ICH (Full form = International Conference on Harmonisation) is a committee that provides the pharmaceutical guidelines for industries.
Quality must be built into the product, it cannot be inspected into it. The Pharmaceutical industries are experiencing a “knowledge and experience deficit” regarding the use of QbD concepts.
FDA’s emphasis on quality by design began with the recognition that increased testing does not improve product quality (this has long been recognized in other industries).In order for quality to increase, it must be built into the product. To do this requires understanding how formulation and manufacturing process variables influence product quality.Quality by Design (QbD) is a systematic approach to pharmaceutical development that begins with predefined objectives and emphasizes product and process understanding and process control, based on sound science and quality risk management. A presentation compiled from material freely available on the WEB to introduce the concepts of QbD for beginners.
The dossier is a collection of documents that contain all the technical data of pharmaceutical products to be approved\ registered\ marketed in a country.
- Whilst the realization of the CTD took many years, there is now a common format for the submission of Marketing Authorizations Applications across the three ICH regions - Europe, Japan and the USA.
- This should facilitate pharmaceutical companies to make simultaneous filings in the ICH regions as it will eliminate the extensive work previously required to convert, for example, a US dossier to an EU dossier and vice versa.
Marv Shepherd, PSM president, Member USP Package Storage and Distribution Expert Committee, and Professor at the University of Texas at Austin speaks about updates to United States Pharmacopeia's good distribution practices.
common technical document vs electronic common technical document MayankGupta851
This presentation deals with brief overview of common technical document and its electronic version that is implemented by three ICH regions and common format for the dossier preparation for NDA application and documents required to prepare types of modules in database in specified format as specified by regulatory authorities.
common technical document and electronic document by akshay trivedi
The CTD is maintained by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The Common Technical Document is divided into five modules: Administrative and prescribing information
The Common Technical Document (CTD) was designed to provide a common format between Europe, USA, and Japan for the technical documen- tation included in an application for the registration of a human pharmaceutical product..
I have created this document with inputs from various sources. Some are taken right from slideshare. I just try to make this topic little compact and lucid, so that everybody can understand it easily
The Common Technical Document (CTD) is a standardized format for regulatory submission of information on drugs, biologics, and medical devices to regulatory authorities in different countries. The CTD is designed to simplify the submission and review process by providing a consistent format and organization of information that can be easily understood by regulatory authorities in different regions.
Similar to PRODUCT REGISTRATION IN THE GLOBAL MARKET WITH CTD (20)
Pharmacovigilance (PV) is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem. Information received from patients and healthcare providers via pharmacovigilance reporting form as well as other sources such as the medical literature, plays a critical role in providing the data necessary for pharmacovigilance to take place.
GMP is the part of Quality Management which ensures that the products are consistently produced and controlled to the quality standard appropriate to their intended use as required by the marketing authorization and product specification.
(Ref. WHO)
The pharmaceutical quality system “assures that the desired product quality is routinely met, suitable process performance is achieved, the set of controls are appropriate, improvement opportunities are identified and evaluated, and the body of knowledge is continually expanded...
Good Manufacturing Practice for Pharmaceutical Products.pdfMd. Zakaria Faruki
According to the WHO-
"GMP is the part of Quality Management which ensures that the products are consistently produced and controlled to the quality standard appropriate to their intended use as required by the marketing authorization and product specification".
CAREER OPPORTUNITIES OF PHARMACY GRADUATES IN THE PHARMACEUTICAL INDUSTRIES.pdfMd. Zakaria Faruki
Pharmacy is a very important profession, which deals with the manufacturing, handing, proper utilization, dispensing, and administration of life saving drugs.
Training means the process of increasing the knowledge and skills of an employee for doing a particular job. It seeks to improve the job performance and work behaviour of those trained.
Process validation is defined as the collection and evaluation of data, from the process design stage throughout production, which establishes scientific evidence that a process is capable of consistently delivering quality products.
The U.S. Food and Drug Administration (FDA) has proposed guidelines with the following definition for process validation: – “PROCESS VALIDATION” is establishing documented evidence which provides a high degree of assurance that a specific process consistently produces a product meeting its predetermined specifications and quality attributes.
Workshop on General Accident Prevention at The workplaces.pdfMd. Zakaria Faruki
Providing a safe environment for employees is one of the most important responsibilities of a management team. In industries with inherent risks, like construction and mining, it's crucial that employees understand and follow the proper safety protocols.
In addition, preventing job accidents call for various strategies. The organization should have a comprehensive education of the workers, proper risk management, introducing safety alerts in the establishments, security leaders, and ensuring that the workers are in a stable psychological and mental state.
Moreover, developing and enforcing safety plans in the organization can provide greater peace of mind for employees and help prevent accidents and injuries. In this Workshop, we discussed what accident prevention in the workplace is and provide tips for maintaining a safe workplace.
Therefore, please follow the safety guidelines accordingly to prevent the accident in the workplace.
The personnel is the most important asset of a company, and the easiest to neglect. The establishment and maintenance of a satisfactory system of quality assurance and GMP relies upon people who develop the system, the people who use the system and the people who examine the system to see if it has worked.
The technical people must have a knowledge and understanding of GMP to enable them to carry out their duties in accordance with GMP. These people must have the level of training and experience that will enable them to do their professional works respectively.
According to US FDA it is illustrated here that,
A recall is a method of removing or correcting products that are in violation of laws administered by the Drug Regulatory Authority.
Recall is a voluntary action that takes place because manufacturers and distributors carry out their responsibility to protect the public health and well-being from products that present a risk of injury or gross deception or are otherwise defective.
21 CFR 7 provides guidance so that responsible firms may conduct an effective recall.
Market or Customer complaint is “an expression of dis-satisfaction on a customer’s behalf to a responsible party” when their expectations have not been met! However, Complaint handling is a Good Manufacturing Practice (GMP) requirement, since all complaints concerning potentially defective products must be carefully reviewed according to a written procedure.
Good Documentation Practice (GDocP) is an essential part of the quality assurance and such, related to all aspects of GMP” this definition is based on WHO. It is a systematic procedure of preparation, reviewing, approving, issuing, recording, storing and archival of document.
GMP is the part of Quality Management which ensures that the products are consistently produced and controlled to the quality standard appropriate to their intended use as required by the marketing authorization and product specification. (Reference: WHO)
In contrast, cGMP i.e. ‘c’ before the GMP is indicative of the constantly changing technologies and systems which are up-to-date in order to comply with the regulations. These the dynamic changes in Good Manufacturing Practice to make Pharmaceuticals manufacture foul proof; assuring a high level of confidence in the safety and efficacy of the product.
Bioequivalence is a term in pharmacokinetics used to assess the expected in vivo biological equivalence of two proprietary preparations of a drug. If two products are said to be bioequivalent it means that they would be expected to be, for all intents and purposes, the same.
The first generation of biological drugs, which
have introduced many revolutionary treatments to life threatening and rare illnesses, is currently facing patent expiration. As a result, research-based and generics pharmaceutical companies alike are pursuing the opportunity to develop “generic” substitutes to original biologics, which are also known as biosimilars.
GCP: An international ethical and scientific quality standard for designing, conducting, recording and reporting clinical trials that involve the participation of human subjects.
PV: The science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem.
Stability study of Pharmaceutical Products and Regulatory Requirements Md. Zakaria Faruki
A marketed product stability program fulfills registration
commitments and ensures that marketed product is
stable until expiry date stamped on product
label....
Stability studies should be planned on the
basis of pharmaceutical R&D and regulatory
requirements...
Post-marketing drug safety surveillance refers to the monitoring of drugs once they reach the market after clinical trials through a process which evaluates drugs taken by individuals under a wide range of circumstances over an extended period.
Pharmacovigilance is the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
PRODUCT REGISTRATION IN THE GLOBAL MARKET WITH CTD
1. TRAINER: MD. ZAKARIA FARUKI
ORION PHARMA LIMITED
DHAKA, BANGLADESH
Slide 1 of 26
TRAINING ON
PRODUCT REGISTRATION
IN THE GLOBAL MARKET
WITH CTD
ORION
2. INTERNATIONAL CONFERENCE ON
HARMONIZATION (ICH)
ICH was formed in April 1990 hosted by EFPIA
(European Federation of Pharmaceutical Industries
and Associations) in Brussels, Belgium
ICH-SC (Steering Committee) has decided that the
Topics selected for harmonization would be divided
into Safety, Quality and Efficacy to reflect the three
criteria which are the basis for approving and
authorizing new medicinal products.
In a broad sense harmonization means a common of
technical requirements for medicines regulation, i.e.,
legislations, guidelines, procedures, etc.
Training on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. Zakaria FarukiFarukiFarukiFaruki
Observers
Slide 2 of 26
ORION
3. WHAT IS CTD?
It is an application format of ICH’s mission is to
make recommendations towards achieving
greater harmonization.
Internationally agreed “well structured common
format” for the organization of the technical
requirements that is to be submitted to the
regulatory authority as an application for the
registration of pharmaceuticals for human use
in all three ICH regions (USA, Europe and
Japan).
Ensure that safe, effective, and high quality
medicines are developed and registered in the
most resource-efficient manner.
Reducing or averting duplication of testing
carried out during the research and
development of new human medicines
Slide 3 of 26
ORION
Training on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. Zakaria FarukiFarukiFarukiFaruki
4. WHY CTD?
To provide a harmonized format / template for
the submission of technical requirement to the
regulatory authorities (FDA) that is acceptable
in all 3 ICH regions.
Reduce the time and save resources used to
compile applications
Eliminate duplicating of activities
It will ease the preparation of electronic
submissions (eCTD)
Companies have to generate only one data set
for all regions, and consequently the amount of
human and animal experimentation is reduced.
Faster access to medicines of high public health
value.
Slide 4 of 26
ORION
Training on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. Zakaria FarukiFarukiFarukiFaruki
5. CTD TRIANGLE
Slide 5 of 26
ORION
Pivotal to
Dossier
However, CTD impacts
Labeling
Training on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. Zakaria FarukiFarukiFarukiFaruki
6. CTD STRUCTURE
CTD contains 5 “Modules”
Module 1 – Administrative & Prescribing
Information
Module 2- All CTD Summaries / Overviews
Module 3 –Quality (M4Q)
Module 4 – Non Clinical Study (M4S)
Module 5 – Clinical Study (M4E)
Module 2-5 are Common in CTD & Module 1 is
Region specific but always to be included in
complete CTD structure.
ORION
Training on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. Zakaria FarukiFarukiFarukiFaruki Slide 6 of 26
7. MODULE 2: CTD SUMMARIES
2.1 Overall CTD ToC
2.2 CTD Introduction
2.3 Quality Overall Summary
2.4 Non-Clinical Overview
2.5 Clinical Overview
2.6 Non-Clinical Written and Tabulated
Summaries
2.7 Clinical Summary
ORION
Training on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. Zakaria FarukiFarukiFarukiFaruki Slide 7 of 26
8. 2.3 QUALITY OVERALL SUMMARIES
(QOS)
A Summary that follows the scope and
outline of the Body of Data in Module 3
Emphasize and discuss critical key
parameters of the product
Discuss key issues to integrate information
from Module 3 and other modules
Typically 40 pages (Less than 50 Pages),
excluding tables, figures
ORION
Training on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. Zakaria FarukiFarukiFarukiFaruki Slide 8 of 26
9. 2.4 NONCLINICAL OVERVIEW
2.4.1 Overview of Nonclinical Testing Strategy
2.4.2 Pharmacology
2.4.3 Pharmacokinetics
2.4.4 Toxicology
2.4.5 Integrated Overview and Conclusions
2.4.6 List of Literature Citation
Non-clinical data with it’s interpretation
Clinical relevance of findings. Typically 50-400 pages
(excluding tables)
Implications of the findings for the safe use of the
product.
ORION
Training on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. Zakaria FarukiFarukiFarukiFaruki Slide 9 of 26
10. 2.5 CLINICAL OVERVIEW
2.5.1 Product development rationale
2.5.2 Overview of Biopharmaceutics
2.5.3 Overview of Clinical Pharmacology
2.5.4 Overview of Efficacy
2.5.5 Overview of Safety
2.5.6 Benefits and Risks Conclusions
2.5.7 References
Critical analysis of clinical data for efficacy and
safety, as well as other relevant information.
Typically this section should coved by 30 pages.
ORION
Training on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. Zakaria FarukiFarukiFarukiFaruki Slide 10 of 26
11. 2.6 NONCLINICAL WRITTEN AND
TABULATED SUMMARIES
2.6.1 Introduction
2.6.2 Written Summary of Pharmacology
2.6.3 Tabulated Summary of Pharmacology
2.6.4 Written Summary of Pharmacokinetics
2.6.5 Tabulated Summary of Pharmacokinetics
2.6.6 Written Summary of Toxicology
2.6.7 Tabulated Summary of Toxicology
Typically This section consist of 100-150 pages
ORION
Training on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. Zakaria FarukiFarukiFarukiFaruki Slide 11 of 26
12. 2.7 CLINICAL SUMMARY
2.7.1 Summary of biopharmaceutic studies
and associated analytical methods
2.7.2 Summary of clinical pharmacology
2.7.3 Summary of clinical efficacy
2.7.4 Summary of clinical safety
2.7.5 References
2.7.6 Synopses of individual studies
Detailed summarization of the clinical information in
module 5. Typically 50-400 pages (excluding tables)
Post marketing data for products that have marketed in
other regions to be incorporated.
ORION
Training on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. Zakaria FarukiFarukiFarukiFaruki Slide 12 of 26
13. MODULE 3: QUALITY
Chemical-pharmaceutical information and
biological information (CMC)
Table of content to direct reviewer around
the document
Provide body of data as follow:
Section S Section P
Section A Section R
Section C
ORION
Training on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. Zakaria FarukiFarukiFarukiFaruki Slide 13 of 26
14. SUBMISSION OF CMC
INFORMATION IN CTD FORMAT
(Cont’d…)
3.2.S
3.2.S.1
3.2.S.2
3.2.S.3
3.2.S.4
3.2.S.5
3.2.S.6
3.2.S.7
DRUG SUBSTANCE
General Information
Manufacture
Characterization
Control of Drug Substance
Reference Standards or Materials
Container Closure System
Stability
ORION
Training on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. Zakaria FarukiFarukiFarukiFaruki Slide 14 of 26
15. SUBMISSION OF CMC
INFORMATION IN CTD FORMAT
3.2.P
3.2.P.1
3.2.P.2
3.2.P.3
3.2.P.4
3.2.P.5
3.2.P.6
3.2.P.7
3.2.P.8
DRUG PRODUCT
Description & Composition of the FPP
Pharmaceutical Development
Manufacture
Control of Excipients
Control of Drug Product
Reference Standards or Materials
Container Closure System
Stability
ORION
Training on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. Zakaria FarukiFarukiFarukiFaruki Slide 15 of 26
16. APPENDIX, REGIONAL
INFORMATION & LITERATURE
REFERENCES
3.2.A APPENDICES
3.2.A.1 Facilities and Equipments
3.2.A.2 Adventitious Agents safety
evaluation
3.2.A.3 Novel excipients
3.2.R REGIONAL INFORMATION
3.2.R.1 Production documentation
3.2.R.2 Executed production documents
3.2.R.3 Master production documents
3.3 LITERATURE REFERENCES
Training on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. Zakaria FarukiFarukiFarukiFaruki
ORION
Slide 16 of 26
17. MODULE 4: NON CLINICAL
4.1 TABLE OF CONTENTS
4.2 STUDY REPORTS
4.2.1 Pharmacology
4.2.2 Pharmacokinetics
4.2.3 Toxicology
4.3 LITERATURE REFERENCES
Training on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. Zakaria FarukiFarukiFarukiFaruki
ORION
Slide 17 of 26
18. Module 5: Clinical Study
5.1 Table of Contents
5.2 Tabular Listing of all Clinical Studies
5.3 Clinical Study Reports
5.3.1 Reports of Biopharmaceutics Studies
5.3.2 Reports of Studies Pertinent to PK using Human Biomaterials
5.3.3 Reports of Human Pharmacokinetic (PK) Studies
5.3.4 Reports of Human Pharmacodynamic Studies
5.3.5 Reports of Efficacy and Safety Studies
5.3.6 Reports of Post-marketing Experience
5.3.7 Case Report forms and Individual Patient Listings
5.4 Literature References
Training on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. Zakaria FarukiFarukiFarukiFaruki
ORION
Slide 18 of 26
19. GUIDANCE FOR THE INDUSTRY
Training on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. Zakaria FarukiFarukiFarukiFaruki
ORION
Slide 19 of 26
20. ICH STATUS OF
HARMONIZATION INITIATIVE
Training on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. Zakaria FarukiFarukiFarukiFaruki
ORION
Slide 20 of 26
21. ADVANTAGES OF CTD…
• Provides a Harmonized format for the submission
of information for regulatory authorities
• Harmonized format allowing electronic
transmission
• To save time and resources
• To facilitate regulatory review and
communications
• Easy to understand and evaluation of data
• Networking of institutions in developing and
developed countries is an important element in
building regulatory capacity and trust
Training on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. Zakaria FarukiFarukiFarukiFaruki
ORION
Slide 21 of 26
22. ADVANTAGES OF CTD
Applicable to all types of products (NCE,
NDA, ANDA, radiopharmaceuticals,
vaccines, herbals, etc.)
Enabled implementation of good review
practices
Facilitation of response to questions
Partially identical data package
No actual increase in EU and / or Japanese
application size/review time
Training on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. Zakaria FarukiFarukiFarukiFaruki
ORION
Slide 22 of 26
23. LIMITATIONS………
CTD is only a format, its not a single dossier
with a single content.
Legal requirements differ in three regions
ICH guidelines have not yet harmonized in all
requirements
Pharmacopoeias are not harmonized
Applicant may have regional preferences.
No detailed information about content of
dossier
Which studies/data required for a successful
approval
Still not identical for all regions (different
regional requirements)
Training on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. Zakaria FarukiFarukiFarukiFaruki
ORION
Slide 23 of 26
24. CONCLUSION
Whilst the realization of the CTD took many years,
there is now a common format for the submission
of Marketing Authorizations Applications across
the three ICH regions –
Europe
Japan and
USA
This should facilitate pharmaceutical companies to
make simultaneous filings in the ICH regions as it
will eliminate the extensive work previously
required to convert, for example, a US dossier to
an EU dossier and vice versa.
Training on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. Zakaria FarukiFarukiFarukiFaruki
ORION
Slide 24 of 26
25. ORION
Training on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. Zakaria FarukiFarukiFarukiFaruki Slide 25 of 26
“Hesitating to act
because the
whole vision
might not be
achieved, or
because other do
not yet share it,
is an attitude that
only hinders
progress.”
‐‐‐‐M. K. Gandhi
26. ORION
Training on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. ZakariaTraining on CTD Conducted by Md. Zakaria FarukiFarukiFarukiFaruki Slide 26 of 26